PLATINUM-RESISTANT OVARIAN CANCER

This study tests a new drug, MGC026, in 250 adults with advanced solid tumors that have not responded to other treatments. The goal is to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive the drug by IV and are closely monitored f…

This study tests a new drug called CBX-12 in 40 women with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if CBX-12 can shrink tumors or stop them from growing, and to check for side effects. Participants will receive one of two dose…

This study tests a new treatment for people with ovarian cancer that no longer responds to platinum-based chemotherapy. The treatment uses a person's own immune cells, which are specially trained in a lab to attack cancer, combined with a drug that boosts their activity and stand…

This early-phase trial tests a one-time treatment called OPB-101 for people with ovarian cancer that no longer responds to platinum chemotherapy. The therapy uses a patient's own immune cells, modified in a lab to better target and attack cancer cells. The main goals are to check…

This early-phase study tests a new daily pill, NKT3964, that breaks down a protein called CDK2 to slow cancer growth. It is for adults with advanced solid tumors (like ovarian, endometrial, breast, gastric, or lung cancer) that have not responded to standard treatments. The study…

This early-phase trial tests a new drug called MOv18 IgE in people with advanced ovarian, endometrial, or triple-negative breast cancers that have a specific marker (folate receptor alpha). The study has two parts: first, finding a safe dose, and then checking how well that dose …

This early-stage study tests a new drug called MEN2501 in about 100 adults with ovarian cancer that has stopped responding to platinum-based chemotherapy. The main goals are to find a safe dose and check for side effects. Researchers will also watch for signs that the drug is shr…

This early-phase study tests a new drug called HWK-007 in people with advanced solid tumors, including certain ovarian, endometrial, and lung cancers. The drug is designed to target a protein (PTK7) found on cancer cells and deliver a chemotherapy-like payload directly to them. T…

This study tests a new drug called lorigerlimab in people with advanced ovarian or other gynecologic cancers that no longer respond to standard chemotherapy. About 60 participants will receive the drug by IV every 3 weeks. The goal is to see if the drug can shrink tumors and to c…

This study tests a new drug called IN10018 combined with standard chemotherapy for people with a tough-to-treat type of ovarian cancer that no longer responds to platinum-based treatments. About 150 adults will join to see if the combo is safe and shrinks tumors. The goal is to f…

This early-phase study tests a new drug called HWK-016 in people with advanced ovarian or endometrial cancers that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to find the safest d…

This study tests whether a cancer-killing virus (Olvi-Vec) given into the abdomen can make platinum-resistant ovarian cancer respond to chemotherapy again. About 186 women whose cancer has not responded to at least three prior treatments will receive either Olvi-Vec plus chemo an…

This early-phase study tests a new treatment called CIML NK cell therapy for people with recurrent ovarian cancer that no longer responds to platinum-based chemotherapy. The therapy uses specially trained natural killer cells from a donor to attack the cancer. The study aims to f…

This early-phase study tests a new drug called CTIM-76 in people with ovarian, testicular, or endometrial cancer that has come back or stopped responding to standard treatments. The drug works by helping the immune system attack cancer cells that have a specific marker called CLD…